If you liked this article you might like

Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
Allergan's Boldness may not be Limited to Tobira Deal
16 Biopharma Companies Besides Medivation That Are Attractive Targets
Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium